TRAW

#4802
Traws Pharma, Inc. - Common Stock
0.5 8 USD
-0.02%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.58
0.60
Jahresspanne
0.43
3.25
Tagesänderung
-1.69%
Monatliche Änderung
+23.40%
6 month change
-64.85%
Jahresänderung
-56.72%
Vorheriger Schlusskurs
0.5 9
Open
0.5 8
Tief
0.5 8
Hoch
0.6 0
Volumen
6
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Traws Pharma, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Traws Pharma, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Traws Pharma, Inc. current report, Q2 FY2026
8-K

Traws Pharma, Inc. current report, Q1 FY2020

Full document

Business Context and Reporting Period

This Form 8-K is filed by Onconova Therapeutics, Inc. (not Traws Pharma, Inc., as indicated in the metadata) for the reporting period of January 15, 2020. The registrant is a Delaware corporation with its principal executive offices in Newtown, PA. The company's common stock (ONTX) and warrants (ONTXW) are listed on The Nasdaq Stock Market LLC.

Key Financial Metrics

The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding a securities listing.

Material Changes and Events

  • Nasdaq Public Reprimand: On January 15, 2020, the Company received a public reprimand letter from Nasdaq regarding a violation of Listing Rule 5635(d).
  • Violation Details: The violation concerned an offering completed on November 25, 2019, involving 55,000,000 shares of common stock (or equivalents) and warrants to purchase 55,000,000 shares.
  • Regulatory Determination: Nasdaq determined the offering was not a "public offering" as defined by Rule IM-5635-3. Consequently, the issuance of more than 20% of pre-offering shares at a price below the minimum required for non-public offerings necessitated shareholder approval, which was not obtained.
  • Sanction: Nasdaq determined that delisting was not an appropriate sanction and closed the matter with a public reprimand under Listing Rule 5810(c)(4).

Outlook, Risks, and Management Commentary

Management Commentary: The Company stated that based on Nasdaq's published rules and guidance at the time of the November 2019 offering, it believed the transaction qualified as a "public offering" under Rule 5635(d).

Impact on Listing: The receipt of the reprimand letter has no effect on the continued listing of the Company's common stock on Nasdaq.

Risks: The filing highlights the risk of regulatory interpretation differences regarding the definition of a "public offering" and the requirement for shareholder approval for significant equity issuances.

Investor Verification Checklist

  • Verify the current trading status of ONTX and ONTXW on Nasdaq to confirm no subsequent delisting actions have occurred.
  • Review the November 25, 2019 Form 8-K to understand the original terms and pricing of the 55,000,000 share offering.
  • Confirm whether the Company has implemented internal controls to ensure future offerings meet Nasdaq shareholder approval requirements.
  • Check for any subsequent correspondence from Nasdaq regarding the reprimand or future compliance.